Pretransplant conditioning with IV busulfan (Bu) and fludarabine (Flu) as alternative to Bu and cyclophosphamide (Cy)—a safe, myeloablative regimen with high antileukemic efficacy in AML/MDS  by de Lima, M. et al.
followed with a standard autologous transplant approach. Long-
term efﬁcacy of this therapy and its impact upon disease-free
and overall survival still has not been established, but is the
subject of this ongoing trial.
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PRETRANSPLANT CONDITIONING WITH IV BUSULFAN (BU) AND FLU-
DARABINE (FLU) AS ALTERNATIVE TO BU AND CYCLOPHOSPHAMIDE
(CY)—A SAFE, MYELOABLATIVE REGIMEN WITH HIGH ANTILEUKEMIC
EFFICACY IN AML/MDS
de Lima, M.1; Couriel, D.1; Shahjahan, M.1; Alamo, J.1; Madden, T.1;
Thapar, N.1; Russell, J.2; Anderlini, P.1; Giralt, S.1; Shpall, E.1; Jones,
R.1; Champlin, R.1; Andersson, B.1 1. The University of Texas M.D.
Anderson Cancer Center, Houston, TX; 2. Alberta BMT Program,
Canada
Background: As an alternative to Cy in combination with IV Bu
as preparation for allogeneic stem cell transplantation (AlloSCT),
we proposed that Flu, which does not depend on the hepatic
GSH/GST pathways for its metabolism, would yield improved
safety, yet retained antileukemic efﬁcacy. We have now compared
a series of patients receiving pretransplant conditioning therapy
with IV Bu-Flu to that of a previous group conditioned with the IV
BuCy2 regimen.Methods: Flu 40 mg/m2 IV was given once daily,
each dose followed immediately by Bu 130 mg/m2 IV over 3 hr
(days 6 till 3). In the IV BuCy2 Bu was given at 0.8 mg/kg over
2 hr every 6 hr for 16 doses (days 7 till 4), followed by Cy 60
mg/kg on days 3 and 2. Patients with an unrelated (MUD) or
mismatched donor received ATG on days 3 to 1. Graft-versus-
host disease (GVHD) prophylaxis was based on tacrolimus and
mini-methotrexate. Results: Median age was 46 (19–66) years
(Bu-Flu group, n128 patients) and 39 (13–64) years (BuCy
group, n72 patients), respectively. At the time of transplant 45%
and 46% patients in each group were in CR1-3, the remainder had
active disease. Cytogenetic risk category group was poor or inter-
mediate in 88% of the patients in the IV Bu-Flu and in 82% of the
BuCy2 group. Donors were HLA-identical siblings (SIBS) in 53%,
and 73%, MUDs in 39% and 15%, others in 8% and 12%,
respectively in the Bu-Flu and BuCy2 groups. Median follow-up
for patients alive (October 2004) was 16.5 mos (6–40; n78) for
the IV Bu-Flu group, and 47 mos (24–76; n26) for BuCy pa-
tients. 100-day treatment-related mortality (TRM) was for SIB/
MUD 2.7/2% after IV Bu-Flu, and 7/9% in the BuCy2 group,
respectively. Overall, one-year TRM was for 7% after Bu-Flu and
18% after BuCy2. The overall aGvHD rates were 42% and 45%.
The 2-year overall survival (OS) was 50% for the whole IV Bu-Flu
group, 42% after IV BuCy2. For patients transplanted in CR the
2-yr OS and event-free survival were 69% and 68% after IV
Bu-Flu, and 48% and 41% in the IV BuCy2 (p0.03). Table shows
pharmacokinetics data. Conclusions: IV Bu-Flu is a safe, reduced
toxicity myeloablative-conditioning regimen when used in the
AML/MDS patient population. Its antileukemic efﬁcacy appears to
be at least comparable to that experienced with the IV BuCy2
regimen. Our data demonstrate that the IV Bu-Flu regimen should
be considered as a new standard for myeloablative conditioning
therapy for alloSCT in AML/MDS.
Parameter (units)
Q Day IV Bu
(CV%)
Q 6 H IV Bu
(CV%)
Cmax (ug/ml) 3.6 (14) 1.2 (19.7)
Vd (L/m2) 22.56 (20.2) 22.65 (21.3)
Clearance (ml/min/m2) 109.3 (26) 116.4 (24)
T1/2 (hours) 2.73 (27.5) 2.91 (25)
AUC (M  min) 4,925 (25.5) 1,292 (25)
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IDENTIFICATION OF NOVEL WT1 EPITOPES BY SENSITIZATION OF
HUMAN T CELLS WITH OVERLAPPING PENTADECAPEPTIDES SPAN-
NING THE WT1 PROTEIN FOR THE TARGETED ADOPTIVE IMMUNO-
THERAPY OF LEUKEMIA
Doubrovina, E.; Dupont, J.; Trivedi, D.; O’Reilly, R.J. Memorial
Sloan-Kettering Cancer Center, New York, NY
The oncofetal protein, WT1, is differentially expressed in 60–
80% of acute leukemias and CML. Previously, four peptide
epitopes presented by HLA-A0201 or HLA-A2402 have been
identiﬁed. We hypothesized that other epitopes presented on the
same or different HLA alleles may be key players in WT1 speciﬁc
anti-tumor T cell response. We used a pool of 15-mers with 10
amino acid overlaps spanning the full sequence of WT1, loaded on
autologous monocytes-derived dendritic cells or EBV-transformed
BLCL to sensitize and raise T cell lines from 9 normal donors
expressing or not expressing HLA-A0201 or HLA-A2402. Speciﬁc
15-mers eliciting responses were identiﬁed by quantitating IFN
CD8 or CD4 T cell responses to secondary stimulation with
15-mer subpools organized in a mapping grid with single overlaps.
Cytolytic responses against targets loaded with the identiﬁed stim-
ulating 15-mer and sharing single HLA class I or II alleles permit-
ted identiﬁcation of restricting HLA alleles in standard 51Cr re-
lease assay. Individuals inheriting HLA-A0201 have generated
CD8 T cells in response to the complete pool which are selec-
tively reactive against single 15-mers containing the known im-
munogen 252–260RMFPNAPYL. However, in certain donors,
responses to other 15-mers 28 and 33, containing heretofore un-
reported epitopes 136–144ALLPAVPSL and 163–171VLDFAP-
PGA accordingly have been dominant and restricted by the HLA-
A0201 allele. By mapping responses of T cells sensitized with the
complete pool, deﬁning the presenting HLA alleles and delineating
immunogenic sequences within speciﬁc 15-mers, additional novel
epitopes presented by HLA-B0801, DRB10301 and DRB10402 for
both CD8 and CD4 WT1 speciﬁc T cells have also been
deﬁned. CTL generated by this approach also lysed both peptide-
loaded targets as well as primary WT1 leukemic cells expressing
the restricting HLA allele. Thus, sensitization with pools of over-
lapping synthetic 15-mers spanning WT1has made possible iden-
tiﬁcation of several new immunodominant HLA class I and II
WT1 epitopes which selectively stimulate both CD8 and CD4
WT1-speciﬁc T cell lines that are leukemocidal and therefore of
possible use for extending the potential of WT1 speciﬁc T cells for
adoptive immunotherapy to patients with WT1 tumors not ex-
pressing HLA-A0201 or A2402.
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